BMP9, a member of the TGF-β superfamily, has been demonstrated by Wang et al. [42] to promote EMT changes in a dose-dependent manner; the authors have also commented that BMP9-induced EMT may be partially responsible for BMP9-induced Cisplatin chemoresistance in ovarian cancer. This evidence concerns the gene TGFB1 and ovarian carcinoma.